本文關鍵詞：基于戰(zhàn)略轉型的P醫(yī)藥公司資產(chǎn)重組方案設計　出處：《東華大學》2017年碩士論文　論文類型：學位論文

  更多相關文章： 醫(yī)藥企業(yè) 戰(zhàn)略轉型 資產(chǎn)重組 資產(chǎn)剝離 股權轉讓

【摘要】：在醫(yī)藥新政的背景下,國家對醫(yī)藥行業(yè)未來發(fā)展道路的指引將進一步推動醫(yī)藥行業(yè)的資產(chǎn)重組�？v觀醫(yī)藥行業(yè)發(fā)展趨勢,“跑馬圈地”,并購重組高潮迭起,醫(yī)藥上下產(chǎn)業(yè)鏈之間的新一輪重組浪潮已開始席卷全國。目前已有越來越多的醫(yī)藥企業(yè)選擇通過資產(chǎn)重組來解決如何直面競爭、研判形勢、確定戰(zhàn)略及其匹配措施等難題,資產(chǎn)重組成為醫(yī)藥企業(yè)戰(zhàn)略轉型的重要途徑。因此,如何從戰(zhàn)略轉型的視角,來制定醫(yī)藥企業(yè)資產(chǎn)重組方案,成為一個有價值的研究課題。本文在實際調研P醫(yī)藥公司的基礎上開展論文研究。研究目的主要體現(xiàn)在兩個方面:一方面為P醫(yī)藥公司設計一套順應其戰(zhàn)略轉型需求的資產(chǎn)重組方案;另一方面通過該方案的設計研究,以期為我國醫(yī)藥企業(yè)資產(chǎn)重組方案設計提供借鑒和幫助。本文共分六個部分,首先在緒論部分對該課題的研究背景和意義做了分析與總結。第二、三部分從企業(yè)戰(zhàn)略轉型和資產(chǎn)重組的基本理論入手,通過研究戰(zhàn)略轉型的類型和資產(chǎn)重組的動因、運作模式、影響因素分析,深入理解相關理論內涵。同時,根據(jù)資產(chǎn)重組方案設計中涉及到的三個難點問題進行深入分析,即資產(chǎn)評估方法的選擇、重組主體的選擇和支付方式的選擇,為p醫(yī)藥公司資產(chǎn)重組方案設計提供了理論依據(jù)。第四部分從宏觀和微觀環(huán)境分析出發(fā),揭示p醫(yī)藥公司戰(zhàn)略管理現(xiàn)狀及其發(fā)展戰(zhàn)略中存在的問題,通過比較戰(zhàn)略轉型中內生式、外延式和內生式與外延式相結合三種方法的優(yōu)劣,確定最適合p醫(yī)藥公司采取的發(fā)展戰(zhàn)略:即以并購重組或戰(zhàn)略聯(lián)盟為主的外延式發(fā)展戰(zhàn)略。第五部分,結合p醫(yī)藥公司實際,從資產(chǎn)重組促進公司戰(zhàn)略重組的角度出發(fā),提出解決問題的路徑,確定先分立后吸收合并的資產(chǎn)重組方案,即:首先完成對p醫(yī)藥公司和y連鎖零售藥店的分立,將從兩公司分離出來的房地產(chǎn)資產(chǎn)組建新公司;然后選擇合適的重組主體,對兩公司的剩余資產(chǎn)進行股權轉讓;其次對新組建的公司分兩次進行吸收合并,將其資產(chǎn)并入S公司股份直接管理。同時,根據(jù)資產(chǎn)重組的影響因素研究,對P醫(yī)藥公司資產(chǎn)重組中的三個難點問題,即資產(chǎn)剝離、重組主體選擇和股權轉讓策略,逐步進行方案設計。方案設計過程中,還針對剝離范圍的選擇、股權轉讓交易支付模式的確定進行優(yōu)劣比較,從而建立了一套適應P醫(yī)藥公司戰(zhàn)略轉型發(fā)展的資產(chǎn)重組方案。第六部分在第五部分資產(chǎn)重組方案設計的基礎上,進一步討論設計方案在資源互補,企業(yè)能力、文化與戰(zhàn)略,重組后整合方法三個層面的作用,對方案的可行性進行定性檢驗。
[Abstract]:In medicine under the background of the new deal, the national guidelines for the future development path of the pharmaceutical industry will further promote the pharmaceutical industry asset restructuring. Throughout the development of the pharmaceutical industry trends, staking, mergers and acquisitions climax, pharmaceutical industry chain between a new round of restructuring tide has been sweeping the country. There are more and more selection of pharmaceutical enterprises through asset restructuring to solve how to face the competition, judged the situation, determine the strategy and measures, the problem of asset restructuring has become an important way of transformation of pharmaceutical enterprise strategy. Therefore, how to transition from a strategic perspective, to develop the pharmaceutical enterprise restructuring plan, become a valuable research topic of this dissertation. Based on the actual investigation of P pharmaceutical company. The purpose of the study is mainly reflected in two aspects: one is to design a strategy to comply with the P pharmaceutical company Asset restructuring program demand; on the other hand through the design of the project, in order to provide reference and help for the design of China's pharmaceutical enterprises asset reorganization scheme. This paper is divided into six parts. The first part of the introduction of the background and significance of the research are analyzed and summarized. The second, third part is the basic theory of from the enterprise strategic restructuring and asset restructuring, motivation types through the study of strategic transformation and reorganization mode, influence factor analysis, in-depth understanding of the relevant theoretical connotation. At the same time, according to the in-depth analysis related to the three difficult problems of design asset restructuring program, namely asset evaluation methods, the main body of the reorganization selection and payment options, and provides a theoretical basis for the design of P pharmaceutical company asset restructuring scheme. In the fourth part, from the macro and micro environment analysis, reveal the P pharmaceutical company strategy Present situation and development strategy of management problems, by comparing the strategic transformation of endogenous and epitaxial and endogenous and epitaxial combination of three methods to determine the most suitable developmental strategy of P pharmaceutical company to take to the mergers and acquisitions or strategic alliance based extension type development strategy. The fifth part combined with the actual, P pharmaceutical company, reorganization of assets from the perspective of promoting the restructuring of the company's strategy, put forward the path to solve the problem, determine the asset restructuring program, the first division after merger: complete separation of P pharmaceutical companies and Y retail chain pharmacies will be separated from the first, two of the company's real estate assets to form a new company then select the appropriate subject; restructuring, equity transfer of the remaining assets of the two companies; followed by the newly formed company for two times merger, the assets management company's shares directly into the S. At the same time, According to the research on the influencing factors of asset restructuring, the three difficult problems of asset reorganization in P pharmaceutical company, namely asset stripping, restructuring choice and equity transfer strategy, design gradually. The design process for stripping range selection are compared to determine the equity transfer payment mode, so as to establish a set of asset restructuring program development strategy of P pharmaceutical company. In the sixth part to the fifth part of the design basis of asset restructuring program, further discussion of enterprise capability design in complementary resources, culture and strategy, after the reorganization of three aspects of integration method, qualitative analysis of the feasibility of the scheme.

【學位授予單位】：東華大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：F426.72;F406.7;F271

【參考文獻】

相關期刊論文 前10條

1 楊璐;;基于上市公司并購的企業(yè)價值收益法評估問題與改進研究[J];商業(yè)會計;2015年19期

2 靳彥斌;;淺談我國上市公司資產(chǎn)重組的問題及對策[J];財會研究;2015年10期

3 宋霞;郭涵予;;我國上市公司并購重組價值評估方法的選擇[J];財會月刊;2015年22期

4 胡雪峰;吳曉明;;醫(yī)藥企業(yè)并購戰(zhàn)略對企業(yè)績效的影響——基于我國上市企業(yè)數(shù)據(jù)的實證分析[J];世界經(jīng)濟與政治論壇;2015年02期

5 謝靜妍;;我國醫(yī)藥行業(yè)并購重組的現(xiàn)狀分析[J];時代金融;2014年33期

6 都蘭娜;寺林嘎;;創(chuàng)新戰(zhàn)略驅動背景下的醫(yī)藥企業(yè)發(fā)展探究[J];經(jīng)營管理者;2014年29期

7 劉西國;徐偉;王健;;基于效率視角的醫(yī)藥行業(yè)集中度提升路徑研究[J];工業(yè)技術經(jīng)濟;2013年01期

8 丁輝;;對我國醫(yī)藥行業(yè)并購重組發(fā)展趨勢的探討[J];江蘇科技信息;2011年03期

9 于江;;中國醫(yī)藥企業(yè)發(fā)展戰(zhàn)略研究[J];中國高新技術企業(yè);2011年09期

10 馬馳騁;;我國有限責任公司股權對外轉讓制度研究[J];四川理工學院學報(社會科學版);2010年02期

相關碩士學位論文 前10條

1 常姣潔;非上市醫(yī)藥制造企業(yè)的價值評估方法探究[D];云南大學;2015年

2 陳園園;EY制藥公司的藥品研發(fā)戰(zhàn)略研究[D];蘇州大學;2014年

3 朱立文;企業(yè)資產(chǎn)重組的價值創(chuàng)造研究[D];海南大學;2014年

4 葛婷婷;論有限責任公司股權外部轉讓制度[D];揚州大學;2013年

5 樊琳琳;中國醫(yī)藥上市公司并購績效的實證研究[D];山東大學;2010年

6 賀慧惠;我國醫(yī)藥制造業(yè)企業(yè)并購行為研究[D];武漢理工大學;2006年

7 趙艷海;企業(yè)戰(zhàn)略性并購[D];貴州大學;2006年

8 李毅勇;通化醫(yī)藥企業(yè)戰(zhàn)略聯(lián)盟式發(fā)展研究[D];吉林大學;2006年

9 胡怡;中國醫(yī)藥行業(yè)并購績效研究[D];東華大學;2006年

10 劉恩棟;論制藥企業(yè)并購的稅收籌劃[D];西南財經(jīng)大學;2005年

，

本文編號：1408232